Treg/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients

Table 1 Clinical data of patients with systemic sclerosis, enrolled in the study

Patient No.	Gender	Age	Form	Stage	Active SSc	Visceral damage	Autoantibodies1	Treatment regimen
1	M	50	dcSSc	Intermediate	Yes	No	Speckled	PMP
2	F	49	dcSSc	Late	No	E	Anti-Scl70	MTX
3	F	55	dcSSc	Intermediate	No	E	Speckled	MP
4	F	58	dcSSc	Late	Yes	PF	Anti-Scl70	PMP, PCYP
5	F	44	dcSSc	Early	Yes	PF	Anti-Scl70	DPA, MP
6	F	27	lcSSc	Early	Yes	No	Anti-Scl70	DPA, MP, TCZ
7	F	48	dcSSc	Early	Yes	PF	Anti-Scl70	DPA, MP
8	F	37	lcSSc	Early	Yes	No	Anti-Ro52	CHQ
9	F	65	dcSSc	Late	No	No	Anti-CENP-A, Anti-CENP-B	MP, CHQ
10	F	36	lcSSc	Intermediate	Yes	No	Speckled	PMP, PCYP, DPA
11	F	47	dcSSc	Early	Yes	SRC	Anti-Scl70	PMP, PCYP
12	F	32	lcSSc	Early	Yes	PF	Speckled	MP, TCZ
13	F	62	dcSSc	Early	Yes	No	Speckled	PMP, PCYP
14	F	27	lcSSc	Late	Yes	No	Anti-PM/Scl-100	MTX
15	F	73	lcSSc	Intermediate	No	PF	Speckled	MP, MTX
16	F	32	dcSSc	Late	Yes	PF	Anti-Scl70, Anti-PM/Scl-75	PMP, PCYP
17	F	60	dcSSc	Late	Yes	No	Speckled	PMP, PCYP
18	F	34	dcSSc	Early	Yes	No	Anti-Scl70	MP, MTX
19	F	56	lcSSc	Late	No	E	Anti-CENP-B	MP
20	F	53	lcSSc	Early	Yes	No	Anti-PM/Scl-75	MP, AZA
21	F	30	lcSSc	Late	Yes	No	Speckled	MP, DPA
22	F	61	dcSSc	Late	No	E, PF, PH	Anti-Scl70	MP
23	F	39	lcSSc	Early	No	No	Anti-CENP-B	MTX
24	F	56	lcSSc	Intermediate	No	E	Speckled	MP, MTX

¹In cases where no SSc specific autoantibody was detected, the staining pattern of patient’s serum on indirect immunofluorescence is shown. F: Female; M: Male; E: Esophageal dysmotility; PF: Pulmonary fibrosis; PH: Pulmonary hypertension; SRC: Scleroderma renal crisis; MP: Methylprednisolone; PMP: Pulse MP; MTX: Methotrexate; CYP: Cyclophosphamide; PCYP: Pulse CYP; DPA: D-penicillamin; CHQ: Chloroquine; TCZ: Tocilizumab; AZA: Azathioprine.